Investment Column: Alliance is not so great for missing rally

Alliance

Our view: Sell

Share price: 309. p (+0.5p)

Alliance Trust's chief executive, Katherine Garrett-Cox, has been saddled with one of those media nicknames that can so easily become a millstone. And that is exactly what "Katherine the Great" has become, given that the performance of Alliance Trust, the gigantic investment trust that she runs, has been anything but.

It was hard to find much to be positive about from yesterday's interim results. The trust was in the bottom quartile of its sector (Global Growth and Global Growth and Income Investment Trusts), having missed out on the stock market's summer rally.

Alliance says that it believes that "in some cases" there has been no fundamental change to the companies whose share prices have soared as a result of the rally. Its argument is that the increase in prices is not "necessarily reflective of any improvement in their underlying value". In other words, the market has got it wrong. That's a brave call for a company like Alliance to make, because if the companies behind the rally – financials, miners, cyclical stocks – retain their value and build on recent gains, Alliance will look rather silly.

Focusing on well-managed companies with healthy balance sheets and good cash flow is a great idea. But you have to pick the right ones as an active manager, otherwise your investors may as well invest in trackers. And tracking the FTSE All World index would have yielded a far better return than Alliance over the past six months. The Trust looks better over the year, but the 15 per cent discount to net asset value in the shares tells its own story. Of course, there is always a prospect of corporate action that could narrow this, but big generalist trusts tend to be difficult to shake up.

Alliance's long-term strategy looks sensible enough, the US and the UK are being focused on for income while Asia is there for growth, but it is not currently producing results, and the discount looms large. Great it may be in the future, but for the present, sell.



Morse

Our view: Hold

Share price: 34.65p (-0.35p)

Morse's woeful performance on the market over the past 18 months is hardly a mystery worthy of the eponymous television detective. The IT company has been battered by the onset of the downturn and falling demand. The stock was at 37.75p when this column last ran the slide rule over it a year ago. We said sell, and it subsequently plumbed the depths to about 4p, before climbing back up again.

Some felt Morse – which resells technology from companies including HP and IBM, as well as providing maintenance and support and business applications – had overstretched. However, it has since been streamlined, and the rocky finances are stabilised.

Morse has overhauled its board, bringing in chairman Kevin Loosemore and chief executive Mike Phillips to start the firefighting and turn the company around. The management also launched a restructuring plan which is now largely completed, and are looking towards growth in 2010.

Morse's annual results earlier this month showed a "very challenging" first nine months, according to Investec, but profits did rise in the fourth quarter. However, whether the server support and maintenance market – its biggest business – will return enough to make it worth a punt is debatable, especially as no dividend is expected until 2012.

Panmure has Morse on a price-to-earnings ratio of 6.6 times forecast full-year earnings, which doesn't look too demanding. But despite the positive end to the year – traditionally the group's strongest quarter – the upside isn't clear enough to pile in yet. The shares aren't likely to sink much either, though, so we feel that we can upgrade our view to a hold.



Allergy Therapeutics

Our view: Buy

Share price: 18.54p (+1.29p)

Despite green shoots now forming part of the everyday lexicon for small-cap biotechnology companies, equity funding is still hard to come by. That is why investors should pay special attention to Allergy Therapeutics, the Aim-listed vaccines group.

The company got a big vote of confidence from the markets, was able to cut much of its debt and restructure its balance sheet after raising £22m in a rights issue earlier this year. Yesterday's preliminary results were also encouraging: research and development spend has fallen from £16.3m to £5.3m after two trials came to an end, leading to a 20 per cent hike in gross profits and a reduced operating loss.

Investors in the biotech industry need share prices to rise (you've more chance of winning the lottery than getting a dividend), and those that bought these shares a year ago have seen their investment jump by 27.8 per cent.

The stock reflects the flow of good news, and while we remain bullish, we caution that the gains made over the last 12 months may not be quite as impressive going forward. Sill, buy.

Start your day with The Independent, sign up for daily news emails
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Retirement Coordinator - Financial Services

Negotiable: Recruitment Genius: To provide a prompt, friendly and efficient se...

Recruitment Genius: Annuities / Pensions Administrator

Negotiable: Recruitment Genius: You will be the first point of contact for all...

Ashdown Group: HR, Payroll & Benefits Officer - Altrincham - up to £24,000.

£18000 - £24000 per annum + benefits: Ashdown Group: HR, Payroll & Benefits Of...

Ashdown Group: Learning and Development Programme Manager

£35000 - £38000 per annum + benefits : Ashdown Group: A highly successful, int...

Day In a Page

The saffron censorship that governs India: Why national pride and religious sentiment trump freedom of expression

The saffron censorship that governs India

Zareer Masani reveals why national pride and religious sentiment trump freedom of expression
Prince Charles' 'black spider' letters to be published 'within weeks'

Prince Charles' 'black spider' letters to be published 'within weeks'

Supreme Court rules Dominic Grieve's ministerial veto was invalid
Distressed Zayn Malik fans are cutting themselves - how did fandom get so dark?

How did fandom get so dark?

Grief over Zayn Malik's exit from One Direction seemed amusing until stories of mass 'cutting' emerged. Experts tell Gillian Orr the distress is real, and the girls need support
The galaxy collisions that shed light on unseen parallel Universe

The cosmic collisions that have shed light on unseen parallel Universe

Dark matter study gives scientists insight into mystery of space
The Swedes are adding a gender-neutral pronoun to their dictionary

Swedes introduce gender-neutral pronoun

Why, asks Simon Usborne, must English still struggle awkwardly with the likes of 's/he' and 'they'?
Disney's mega money-making formula: 'Human' remakes of cartoon classics are part of a lucrative, long-term creative plan

Disney's mega money-making formula

'Human' remakes of cartoon classics are part of a lucrative, long-term creative plan
Lobster has gone mainstream with supermarket bargains for £10 or less - but is it any good?

Lobster has gone mainstream

Anthea Gerrie, raised on meaty specimens from the waters around Maine, reveals how to cook up an affordable feast
Easter 2015: 14 best decorations

14 best Easter decorations

Get into the Easter spirit with our pick of accessories, ornaments and tableware
Paul Scholes column: Gareth Bale would be a perfect fit at Manchester United and could turn them into serious title contenders next season

Paul Scholes column

Gareth Bale would be a perfect fit at Manchester United and could turn them into serious title contenders next season
Inside the Kansas greenhouses where Monsanto is 'playing God' with the future of the planet

The future of GM

The greenhouses where Monsanto 'plays God' with the future of the planet
Britain's mild winters could be numbered: why global warming is leaving UK chillier

Britain's mild winters could be numbered

Gulf Stream is slowing down faster than ever, scientists say
Government gives £250,000 to Independent appeal

Government gives £250,000 to Independent appeal

Donation brings total raised by Homeless Veterans campaign to at least £1.25m
Oh dear, the most borrowed book at Bank of England library doesn't inspire confidence

The most borrowed book at Bank of England library? Oh dear

The book's fifth edition is used for Edexcel exams
Cowslips vs honeysuckle: The hunt for the UK’s favourite wildflower

Cowslips vs honeysuckle

It's the hunt for UK’s favourite wildflower
Child abuse scandal: Did a botched blackmail attempt by South African intelligence help Cyril Smith escape justice?

Did a botched blackmail attempt help Cyril Smith escape justice?

A fresh twist reveals the Liberal MP was targeted by the notorious South African intelligence agency Boss